CAR-T Cells in Treating Patients With Relapsed or Refractory NHL
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of
chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's
lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.